EFFICACY AND SAFETY OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF CANNABINOID RECEPTOR 2, FOR THE TREATMENT OF ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A PHASE 2B RANDOMIZED STUDY

Lin Chang  1     David C. Kunkel  2     Brett A. English  3     Beatriz Lindstrom  3     Sharon Skare  3     Charlie Liu  3     Stewart Turner  3     Fabio Cataldi  3     Saleem Desai  4     Donald Lipkis  5     Jan Tack  6     Brooks D Cash  7     Anthony J. Lembo  8    
1 David Geffen School of Medicine, UCLA, Los Angeles, United States
2 University of California San Diego, La Jolla, United States
3 Arena Pharmaceuticals, Inc., San Diego, United States
4 Los Angeles Gastroenterology, Northridge, United States
5 Sharp Grossmont Hospital, San Diego, United States
6 University Hospitals Leuven, Leuven, Belgium
7 University of Texas Health Science Center Houston, Houston, United States
8 Beth Israel Deaconess Medical Center, Boston, United States

Topic
Disease Mechanisms, Gut Microbiota

Session
IBS

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing